Market Closed -
OTC Markets
01:26:17 16/05/2024 am IST
|
5-day change
|
1st Jan Change
|
1.12
USD
|
+7.69%
|
|
0.00%
|
+9.80%
|
Fiscal Period: October |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
5.058
|
15.42
|
143.5
|
68.39
|
40.23
|
12.89
|
Enterprise Value (EV)
1 |
5.395
|
15.94
|
143.4
|
69.11
|
37.52
|
11.83
|
P/E ratio
|
-0.92
x
|
-8.33
x
|
-8.74
x
|
-5.07
x
|
-3.48
x
|
-1.78
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
5.24
x
|
9.06
x
|
47
x
|
12.2
x
|
6.2
x
|
2.83
x
|
EV / Revenue
|
5.59
x
|
9.37
x
|
46.9
x
|
12.3
x
|
5.78
x
|
2.59
x
|
EV / EBITDA
|
-1.25
x
|
-9.05
x
|
-11.6
x
|
-5.45
x
|
-4.41
x
|
-1.93
x
|
EV / FCF
|
-4.65
x
|
-1,228
x
|
54.4
x
|
44
x
|
-14
x
|
-70.6
x
|
FCF Yield
|
-21.5%
|
-0.08%
|
1.84%
|
2.27%
|
-7.16%
|
-1.42%
|
Price to Book
|
-4.06
x
|
-9.98
x
|
-111
x
|
-25.9
x
|
21.3
x
|
-10.4
x
|
Nbr of stocks (in thousands)
|
2,161
|
2,487
|
4,376
|
5,606
|
7,396
|
7,283
|
Reference price
2 |
2.340
|
6.200
|
32.80
|
12.20
|
5.440
|
1.770
|
Announcement Date
|
06/03/20
|
16/10/20
|
08/02/21
|
14/02/22
|
14/02/23
|
29/01/24
|
Fiscal Period: Oktober |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
0.9645
|
1.702
|
3.056
|
5.597
|
6.491
|
4.558
|
EBITDA
1 |
-4.303
|
-1.762
|
-12.4
|
-12.69
|
-8.51
|
-6.138
|
EBIT
1 |
-4.311
|
-1.776
|
-12.44
|
-12.74
|
-8.843
|
-6.625
|
Operating Margin
|
-446.97%
|
-104.36%
|
-407.03%
|
-227.68%
|
-136.23%
|
-145.33%
|
Earnings before Tax (EBT)
1 |
-3.431
|
-1.738
|
-12.58
|
-12.76
|
-8.897
|
-6.987
|
Net income
1 |
-3.462
|
-1.737
|
-12.58
|
-12.76
|
-8.897
|
-6.987
|
Net margin
|
-358.95%
|
-102.06%
|
-411.78%
|
-227.9%
|
-137.06%
|
-153.28%
|
EPS
2 |
-2.547
|
-0.7441
|
-3.752
|
-2.408
|
-1.564
|
-0.9940
|
Free Cash Flow
1 |
-1.16
|
-0.013
|
2.636
|
1.569
|
-2.687
|
-0.1676
|
FCF margin
|
-120.26%
|
-0.76%
|
86.26%
|
28.04%
|
-41.39%
|
-3.68%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
06/03/20
|
16/10/20
|
08/02/21
|
14/02/22
|
14/02/23
|
29/01/24
|
Fiscal Period: October |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
0.34
|
0.53
|
-
|
0.72
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
0.13
|
-
|
2.71
|
1.06
|
Leverage (Debt/EBITDA)
|
-0.0783
x
|
-0.2982
x
|
-
|
-0.0566
x
|
-
|
-
|
Free Cash Flow
1 |
-1.16
|
-0.01
|
2.64
|
1.57
|
-2.69
|
-0.17
|
ROE (net income / shareholders' equity)
|
145%
|
125%
|
852%
|
629%
|
2,290%
|
-2,158%
|
ROA (Net income/ Total Assets)
|
-1,091%
|
-299%
|
-784%
|
-488%
|
-136%
|
-92.2%
|
Assets
1 |
0.3173
|
0.5815
|
1.605
|
2.616
|
6.546
|
7.579
|
Book Value Per Share
2 |
-0.5800
|
-0.6200
|
-0.3000
|
-0.4700
|
0.2600
|
-0.1700
|
Cash Flow per Share
2 |
0.0200
|
0.0500
|
0.1300
|
0.0200
|
0.5100
|
0.2400
|
Capex
1 |
0
|
0.03
|
0.14
|
0.5
|
0.82
|
0.03
|
Capex / Sales
|
0.47%
|
1.92%
|
4.54%
|
8.86%
|
12.71%
|
0.56%
|
Announcement Date
|
06/03/20
|
16/10/20
|
08/02/21
|
14/02/22
|
14/02/23
|
29/01/24
|
|
1st Jan change
|
Capi.
|
---|
| +9.80% | 6.86M | | +19.13% | 71.69B | | -3.66% | 23.65B | | +9.05% | 9.01B | | +11.24% | 8.64B | | -18.91% | 8.15B | | +15.87% | 5.33B | | +17.83% | 4.35B | | -2.11% | 4.1B | | -2.34% | 3.94B |
Pharmaceuticals Wholesale
|